Oct. 30, 2024 For release: Immediately Refer to: Jordan Bishop; jordan.bishop@lilly.com; (317) 374-1878 (Media) Joe Fletcher; jfletcher@lilly.com; (317) 296-2884 (Investors) Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products • Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue fro ...

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024.Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter and slashed its full-year adjusted profit guidance, sending its stock tumbling roughly 10%.The drugmaker now expects full-year adjusted earnings of between $13.02 to $13.52 per share, down from previous guidance of $16.10 to $16.60 per share. Eli Lilly also lowered the high-end of its revenue outlook ...

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue from the olanzapine portfolio, total revenue increased 42%, and non-incretin revenue increased 17%. Q3 2024 EPS increased to $1.07 on a reported basis and $1.18 on a non-GAAP basis, both inclusive of $3.08 of acquired IPR&D charges. 2024 revenue guidance range updated to $45.4 to $46.0 b ...

Eli Lilly has a number of lucrative opportunities that should serve as tailwinds for sustained growth. For the past couple of years, two of the biggest themes fueling the stock market to new highs are breakthroughs in the weight loss market and euphoria around artificial intelligence (AI). What if I told you that there's a company that operates across both of these opportunities, and that despite a 61% gain in its share price during the past year, the stock is still a compelling buy? Let's explore what's fu ...

Eli Lilly (LLY) will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.03 billion and $1.53 per share, respectively.The strong sales performance of its FDA-approved tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine, Zepbound, helped Lilly deliver exceptionally strong results in the last report quarter. We expect the trend to continue in the third quarter.Tirzepatide is a dual GIP and GLP-1 receptor ...

Eli Lilly and Co LLY will be reporting its third-quarter earnings on Wednesday. Wall Street expects $1.45 in EPS and $12.10 billion in revenues as the company reports at 10 a.m. ET.Is A Stock Split On The Horizon For This Weight Loss Drug Maker?The stock is up 58.31% over the past year, 51.23% YTD. Eli Lilly’s stock has experienced a remarkable rise, recently trading close to $900 a share, down from a record high of about $972. This surge, especially from just $250 two years ago, positions Lilly for a poten ...

One key disease-prevention market is drawing closer to being within reach. As if there weren't enough reasons to buy shares of the cardiometabolic drug juggernauts Eli Lilly (LLY 0.32%) and Novo Nordisk (NVO -0.90%), there's now one more big reason to expect these two stocks to keep climbing. While this new opportunity will take some time to cook before it's ready to delight shareholders, one of the two companies is making significant headway, so it won't be much longer in the grand scheme of things. Here's ...

The odds of its new drug getting established in the U.K. are now much lower.Everyone knows that big pharma companies like Eli Lilly (LLY 0.32%) need to get regulators to agree that their medicines are safe and effective before they can make any money. But regulators aren't the only group the companies need appease before shareholders can see a return.And sometimes, those other groups can throw a wrench into the works, damping long-term growth. As of now, it's looking like Lilly might have stumbled into a pi ...

Analyst Estimates for Q3 2024 Q2 2024 Q3 2023 Revenue $12.18 billion $11.3 billion $9.50 billion Earnings Per Share (Loss) $1.87 $3.28 (6 cents) Net Income (Loss) $1.69 billion $2.97 billion ($57.4 million) Key Metric: Research and Development Costs, Guidance Ahead of Wednesday's earnings announcement, Eli Lilly said it expects to report an IPR&D charge of about $2.83 billion for the quarter, well above the $154 million and $111 million, respectively, the company reported for the first two quarters of the y ...

Eli Lilly logo is screened on a mobile phone for illustration photo. Krakow, Poland on April 9th, ... [+] 2024 (Photo by Beata Zawrzel/NurPhoto via Getty Images) NurPhoto via Getty Images Eli Lilly stock (NYSE: LLY) will report its Q3 results on Wednesday, October 30. The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the consensus estimates. All eyes will be on Eli Lilly's diabetes drug – Mounjaro – and its weight-loss drug – Zepbound. In thi ...